Patisiran
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Amyloidosis, Familial
Conditions
Amyloidosis, Familial, Transthyretin Amyloidosis
Trial Timeline
Mar 27, 2019 → Oct 20, 2020
NCT ID
NCT03862807About Patisiran
Patisiran is a phase 3 stage product being developed by Alnylam Pharmaceuticals for Amyloidosis, Familial. The current trial status is completed. This product is registered under clinical trial identifier NCT03862807. Target conditions include Amyloidosis, Familial, Transthyretin Amyloidosis.
What happened to similar drugs?
0 of 11 similar drugs in Amyloidosis, Familial were approved
Approved (0) Terminated (2) Active (9)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05505838 | Pre-clinical | Completed |
| NCT05023889 | Phase 1 | Active |
| NCT04201418 | Pre-clinical | Completed |
| NCT03862807 | Phase 3 | Completed |
| NCT02510261 | Phase 3 | Completed |
| NCT01617967 | Phase 2 | Completed |
Competing Products
20 competing products in Amyloidosis, Familial